News
-
Smartinhaler developer Adherium Limited has announced that Thomas Lynch has been appointed the company’s new Chairman and that Doug Wilson will step down from the board to take on the role of Medical Director on… Read more . . .
-
Particle characterization specialist Gateway Analytical will move to a new 17,000 sq ft (1,580 sq m) laboratory and office space in Gibsonia, Pennsylvania on September 1, 2016, according to an announcement by its parent company,… Read more . . .
-
According to Vectura, Mundipharma’s Phase 3 trial of the flutiform fluticasone/formoterol MDI failed to demonstrate statistically significant superiority compared to formoterol alone in reducing moderate and severe COPD exacerbations. Mundipharma had planned to seek approval… Read more . . .
-
Boehringer Ingelheim and Qualcomm Life have agreed to collaborate on development of a disposable wireless data sensor module for BI’s Respimat inhaler for COPD treatment. The sensor will connect with Qualcomm Life’s 2net platform. Qualcomm… Read more . . .
-
Daiichi Sankyo has announced that Japanese regulators have approved the use of its Inavir laninamivir octanoate hydrate DPI for the prevention of influenza in single doses of 20 mg for children under 10 years old… Read more . . .
-
Spyryx Biosciences, which is developing an inhaled peptide for the treatment of cystic fibrosis and other respiratory diseases, has announced the appointment of former Sunovion Head of Clinical Research Alistair Wheeler as Chief Medical Officer,… Read more . . .
-
Paradigm Biopharmaceuticals has announced the completion of a Phase 1 clinical trial of its Rhinosul pentosan polysulfate sodium (PPS) nasal spray for allergic rhinitis. Paradigm said that none of the 18 healthy volunteers involved in… Read more . . .
-
According to Pulmatrix, the FDA has granted orphan drug status to the company’s PUR1900 itraconazole DPI for the treatment of fungal lung infections in cystic fibrosis patients, with the FDA stating, “Your designation is based… Read more . . .
-
Molex, which describes itself as “a global manufacturer of complete interconnect solutions,” will acquire device developer and manufacturer Phillips-Medisize from Golden Gate Capital, the company said. The financial terms of were not disclosed. Phillips-Medisize was… Read more . . .
-
Johnson & Johnson has announced that intransal esketamine being developed by its subsidiary Janssen Research & Development has received Breakthrough Therapy Designation from the FDA. According to J&J, the product is in Phase 3 development… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland